1. Current practice in proton therapy delivery in adult cancer patients across Europe.
- Author
-
Tambas, Makbule, van der Laan, Hans Paul, Steenbakkers, Roel J.H.M., Doyen, Jerome, Timmermann, Beate, Orlandi, Ester, Hoyer, Morten, Haustermans, Karin, Georg, Petra, Burnet, Neil G, Gregoire, Vincent, Calugaru, Valentin, Troost, Esther G.C., Hoebers, Frank, Calvo, Felipe A., Widder, Joachim, Eberle, Fabian, van Vulpen, Marco, Maingon, Philippe, and Skóra, Tomasz
- Subjects
- *
CANCER patients , *PROTON therapy , *HEAD & neck cancer , *NATIONAL health services , *PATIENT selection - Abstract
• In total, more than 4000 adult patients are currently treated with PT across Europe annually. • CNS and HNC tumours are the most frequently treated tumour sites. • Most centres use national or institutional guidelines for selecting patients for PT. • Treatments are usually reimbursed by national health care systems. • Most patients are included in prospective data registries and clinical trials. Major differences exist among proton therapy (PT) centres regarding PT delivery in adult cancer patient. To obtain insight into current practice in Europe, we performed a survey among European PT centres. We designed electronic questionnaires for eight tumour sites, focusing on four main topics: 1) indications and patient selection methods; 2) reimbursement; 3) on-going or planned studies, 4) annual number of patients treated with PT. Of 22 centres, 19 (86%) responded. In total, 4233 adult patients are currently treated across Europe annually, of which 46% consists of patients with central nervous system tumours (CNS), 15% head and neck cancer (HNC), 15% prostate, 9% breast, 5% lung, 5% gastrointestinal, 4% lymphoma, 0.3% gynaecological cancers. CNS are treated in all participating centres (n = 19) using PT, HNC in 16 centres, lymphoma in 10 centres, gastrointestinal in 10 centres, breast in 7 centres, prostate in 6 centres, lung in 6 centres, and gynaecological cancers in 3 centres. Reimbursement is provided by national health care systems for the majority of commonly treated tumour sites. Approximately 74% of centres enrol patients for prospective data registration programs. Phase II-III trials are less frequent, due to reimbursement and funding problems. Reasons for not treating certain tumour types with PT are lack of evidence (30%), reimbursement issues (29%) and/or technical limitations (20%). Across European PT centres, CNS tumours and HNC are the most frequently treated tumour types. Most centres use indication protocols. Lack of evidence for PT and reimbursement issues are the most reported reasons for not treating specific tumour types with PT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF